the public sector. This might include STD treatment, for example. If the local or provincial government is paying for a service, it has the right to ensure that the service is of acceptable standard? Other options include making STD drugs or STD syndrome packets available to the private sector at state tender prices. There is always a risk of abuse, but with correct organisation and auditing, abuse could be minimised.

**Education**

Education of doctors and other health workers needs to start with the undergraduate curriculum. Education needs to continue through specialist and postgraduate training, and also to be complemented by a programme of continuing medical education thereafter. Today’s health worker needs to understand the value of evidence-based medicine, standard treatment guidelines, and structured approaches to care.

**CONCLUSION**

STD control must remain a high priority for South Africa. Achieving control is unlikely if the public sector acts alone.23 Many patients seek care in the private medical sector and an effective partnership between it and the public sector needs to be forged. While quality of services can be assessed locally, it seems likely that effective change will only occur within a framework of legislation, financial incentives and continuing education.

**References**


**CORTICAL LENS OPACITIES IN THE YOUNG PATIENT — AN INDICATION FOR A LIPOGRAM?**

**D Meyer, F J Maritz, P H Liebenburg, D P Parkin, L J Burgess**

**Aim.** To determine the characteristics and prevalence of lenticular opacification in patients with underlying dyslipidaemia.

**Methods.** Eighty patients of both genders and all ages (18-90 years) were enrolled in the trial if they met the inclusion criteria for dyslipidaemia.

Patients were included if their fasting serum cholesterol and triglyceride concentrations were &gt; 5.2 mmol/l and &gt; 2.3 mmol/l, respectively, when measured on three separate occasions over a 1-month period.

Patients were excluded if they suffered from any condition known to cause or predispose them to elevated lipid levels or lenticular opacification. Lenticular changes were assessed by means of a slit-lamp through the fully dilated pupil and other physical signs were documented subsequent to thorough physical evaluation.

**Results.** In addition to the classic clinic signs of dyslipidaemia, 31% of patients had cortical lens opacities. Cortical opacities were twice as prevalent as Achilles tendon thickening (16.3%) in our study, the second most prevalent sign of elevated lipid levels. In the subgroup of patients aged under 50 years, 55% had lenticular opacities, predominantly cortical (80%).

**Conclusions.** Cortical lens opacification was the most prevalent sign of dyslipidaemia and it occurred at a relatively young age in our trial population in those patients who were affected. Cortical lenticular opacification should be regarded as an indication for blood lipid profile evaluation.

Department of Ophthalmology, University of Stellenbosch and Tygerberg Hospital, W Cape

**D Meyer, MB ChB, BSc (Pharm), MFGP (SA), MMed (Ophth), FCOphth (SA)**

**P H Liebenburg, 5th year medical student**

Lipid Clinic, Cardiology Unit, Department of Internal Medicine, University of Stellenbosch and Tygerberg Hospital, W Cape

**F J Maritz, MB ChB, MMed (Int), FCP (SA)**

Lipid Clinic, Cardiology Unit, Department of Internal Medicine, and Department of Chemical Pathology, University of Stellenbosch and Tygerberg Hospital, W Cape

**L J Burgess, MB ChB, MMed (Chem Path), PhD**

Department of Pharmacology, University of Stellenbosch and Tygerberg Hospital, W Cape

**D P Parkin, MB ChB, BSc (Pharm), PhD**
Lens opacification and cardiovascular disease are two of the main causes of morbidity worldwide. Lens opacity, manifesting as cataract, is responsible for an estimated 40% of the 42 million cases of blindness in the world. Heart disease, on the other hand, is the single greatest cause of death in developed countries. The relationship between cholesterol and cardiovascular heart disease is well documented. The relationship between cholesterol and lens opacity is, however, far less well appreciated.

Issues relating to drug safety and inherited defects in enzymes mediating cholesterol metabolism have brought renewed attention to a possible interrelationship between lipid metabolism and cataract induction in humans. The lens is unique in that it contains a relative abundance of cholesterol in the fibre cell plasma membrane and furnishes its needs for the latter by on-site biosynthesis. It has been shown that inhibition of cholesterol synthesis in the lens leads to cataract formation in humans.

The Smith-Lemli-Opitz syndrome, mevalonic aciduria and cerebrotendinous xanthomatosis are inherited disorders of cholesterol metabolism and affected patients may present with lens opacities. Triparanol, a hypolipidaemic agent that inhibits cholesterol biosynthesis, was withdrawn from clinical use because of its propensity to induce cataract formation in humans. The very widely used vastatin class of hypolipidaemic medicines are potent inhibitors of cholesterol metabolism and are able to lower serum lipid concentration effectively. Although high ocular safety in older patients over periods of up to 5 years has been reported, it is still not clear whether these agents have the potential to be cataractogenic, particularly in younger patients and over longer periods. The vastatins have been reported to lower mortality effectively in dyslipidaemic patients suffering from heart disease.

In order to assess the prevalence of lenticular opacities in patients with dyslipidaemia (raised serum cholesterol and triglycerides), a group of 80 dyslipidaemic patients were subjected to general physical examination and an ophthalmic examination of the fully dilated eye.

**METHODS**

In order to obtain a study group with maximum homogeneity, only patients meeting the following inclusion criteria were enrolled: (i) male or female (18 - 90 years of age); (ii) high serum total cholesterol (> 5.2 mmol/l); (iii) low high-density lipoprotein (HDL) cholesterol (< 1.8 mmol/l); and (iv) high triglycerides (> 2.3 mmol/l).

Exclusion criteria were: (i) pregnant or lactating women; (ii) severe hypertension (diastolic blood pressure (BP) > 115 mmHg); (iii) history of cardiovascular disease; (iv) diabetes mellitus (fasting blood glucose > 7.8 mmol/l); (v) hypothyroidism, defined as thyroid-stimulating hormone (TSH) > 7.5 mU/l; (vi) any malignant tumour; (vii) significant renal impairment (serum creatinine > 170 μmol/l); (viii) history of pancreatitis; (ix) patient with gallbladder disease, including choledolithiasis; (x) history of gastro-intestinal disease; and (xi) HIV antibody-positive.

Fasting blood samples were obtained from each individual on three occasions over a period of 4 weeks. Patients were only included in the study if their lipid variables adhered to the inclusion criteria on each of the three visits.

All classic physical signs of abnormal lipid variables were documented, namely: (i) xanthomas (on the Achilles tendon, hands, elbows or knees); (ii) palmar yellow striae; (iii) xanthelasma; and (iv) corneal arcus.

Lenticular opacities were classified as being cortical, nuclear or subcapsular on the basis of the characteristics and grading as indicated below:

1. Cortical opacities: (i) water clefts, vacuoles, and flakes - none, few, moderate, or many; (ii) wedges and spokes - involving 1, 2, 3 or 4 quadrants; and (iii) maximal inward extension - minimal, moderate or advanced.
2. Nuclear opacities: (i) tissue discoloration - normal, pale yellow, yellow, dark yellow or brown.
3. Subcapsular opacities: (i) posterior capsule involvement - graded 1 - 4; and (ii) anterior capsule involvement - graded 1 - 4.

A specialist physician and an ophthalmologist examined all the patients.

**RESULTS**

Eighty patients were analysed and Table I reflects their demographic data.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean</th>
<th>Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>53.9</td>
<td>± 11.8</td>
</tr>
<tr>
<td>Blood pressure (mmHg)</td>
<td>143 ± 18</td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>134</td>
<td>± 18</td>
</tr>
<tr>
<td>Diastolic</td>
<td>84</td>
<td>± 9</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>28.29</td>
<td>± 4.82</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Race</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixed race</td>
<td>15 (18.8)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>65 (81.3)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>48 (60)</td>
</tr>
<tr>
<td>Female</td>
<td>32 (40)</td>
</tr>
<tr>
<td>Smokers</td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>23 (27.5)</td>
</tr>
<tr>
<td>Past</td>
<td>34 (42.5)</td>
</tr>
<tr>
<td>Never</td>
<td>23 (27.5)</td>
</tr>
<tr>
<td>Alcohol consumer</td>
<td>55 (68.8)</td>
</tr>
</tbody>
</table>
Most of the study group patients were male, Caucasian and smokers. Most patients (68.8%) admitted to regular alcohol consumption. The mean systolic and diastolic BP data, 134 mm Hg (standard deviation (SD) 18 mm Hg) and 84 mm Hg (SD 9 mm Hg), respectively, fell within the normal range for age. The body mass index (BMI) of the group was significantly greater than the norm, i.e. 28.89 kg/m² (SD 4.82 kg/m²).

Fig. 1 depicts the serum lipid variables. Patients were included in the study only if total serum cholesterol was > 5.2 mmol/l when measured on three separate occasions over a 4-week period, and low-density lipoprotein (LDL) and HDL were uniformly > 2.3 mmol/l and < 1.8 mmol/l, respectively.

The prevalence of lenticular opacities divided the study group into two cohorts, i.e. those with normal lenses (62%) and those with opacities (39%) (Fig. 2).

**Table II. Comparison of subgroup with normal lenses (61%) and the subgroup with lenticular opacities (39%)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Normal (mean ± SD)</th>
<th>Opacity (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>55.3 ± 10.9</td>
<td>54.7 ± 14.8</td>
</tr>
<tr>
<td>Blood pressure (mmHg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>135.6 ± 21.19</td>
<td>140.0 ± 21.81</td>
</tr>
<tr>
<td>Diastolic</td>
<td>84.4 ± 10.03</td>
<td>86.1 ± 9.83</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>28.55 ± 4.84</td>
<td>27.81 ± 4.84</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>7.3 ± 2.01</td>
<td>7.91 ± 2.00</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>5.05 ± 1.54</td>
<td>5.11 ± 1.46</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>1.16 ± 0.39</td>
<td>1.14 ± 0.31</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>2.64 ± 1.89</td>
<td>2.89 ± 1.02</td>
</tr>
<tr>
<td>Uric acid (mmol/l)</td>
<td>3.64 ± 0.91</td>
<td>3.98 ± 1.25</td>
</tr>
</tbody>
</table>

Beaver Dam Eye Study (BDES),* and consequently data for comparison are not available. In the 40 - 50-year age group the prevalence of lenticular opacity in our patients was 50% compared with 4.7% in the BES and 8.3 in the BDES. Differences in the older age groups were not prominent (Table III, Fig. 3).

**Table III. Age distribution of patients with opacities compared with other population-based studies**

<table>
<thead>
<tr>
<th>Age group (yrs)</th>
<th>Percentage of opacities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study group</td>
<td>BES*</td>
</tr>
<tr>
<td>30 - 40</td>
<td>33.33</td>
</tr>
<tr>
<td>40 - 50</td>
<td>50.00</td>
</tr>
<tr>
<td>50 - 60</td>
<td>18.51</td>
</tr>
<tr>
<td>60 - 70</td>
<td>33.33</td>
</tr>
<tr>
<td>70 - 80</td>
<td>66.67</td>
</tr>
<tr>
<td>80+</td>
<td>33.33</td>
</tr>
</tbody>
</table>

BES = Barbados Eye Study; BDES = Beaver Dam Eye Study; N/A = not available.

Fig. 2. Prevalence of lens opacities in the study group.

**Subgroup results**

Comparative analysis with regard to age, BP, BMI, lipid index and uric acid profile did not reveal significant differences between the two subgroups (Table II).

The prevalence of lenticular opacity in dyslipidaemic patients in the 30 - 40-year age group was 33%. This age group was not studied in the Barbados Eye Study (BES)* or the

---

* Beaver Dam Eye Study (BDES)
DISCUSSION

Modern medicine today aspires to the early detection of disease processes, with the aim of early intervention in an attempt either to halt the progression or to reverse the process. Although the classic systemic signs of dyslipidaemia are well appreciated, i.e. xanthomas, xanthelasma, thickening of the Achilles tendon and corneal arcus, in our study the prevalence of one or more of the ocular signs was far greater than that of the systemic signs — 47.3% for the former as opposed to 23.8% for the latter.

The distribution of dyslipidaemia-related signs in our patients was as follows: xanthelasma (7.5%), corneal arcus (8.8%), Achilles tendon involvement (16.3%), and cortical lenticular opacity (31.0%).

It is noteworthy that the most frequent ocular sign, cortical lenticular opacity, occurred twice as frequently as the most frequent systemic sign, Achilles tendon thickening (Fig. 5).

Patients with conditions known to induce lens opacification, e.g. diabetes mellitus, neoplastic disease, hypothyroidism, pancreatitis, renal failure, severe hypertension and HIV/AIDS complex, among others, were meticulously excluded from the trial. Maritz has shown that dyslipidaemic patients have a higher risk of developing adult-onset diabetes mellitus with advancing age than the general population. No patient in the study group had a fasting blood glucose concentration in excess of 7.8 mmol/l, and consequently it is highly unlikely that hyperglycaemia contributed to the high prevalence of cortical opacification.

Most of the patients in the BES were black, and the comparative data from the trial appeared to reveal that black people are at greater risk of developing cortical opacities than Caucasians, and that the latter in turn are at greater risk of developing nuclear opacities.

In contrast to the BES, most of our patients were Caucasians (85%), the rest all being individuals of mixed race. It is possible that capsular opacities are equally prevalent in black and white people and our data provide sufficient motivation for further assessment of this factor in the aetiology of lens opacification.

Defining a cataract is difficult. Harding defines it as 'An opacification of the ocular lens sufficient to impair ocular vision.' We have deliberately steered away from the term cataract because most of the lens changes were not cataracts according to the Harding definition, but rather lenticular opacities as described by the Lens Opacities Classification System II (LOCS II). None of the observed opacities was
severe enough to cause substantial visual impairment.

It has been reported that corneal arcus represents a reliable sign of dyslipidaemia only in patients under 50 years of age and that 60% of patients with periorcular xanthelasma are normolipidaemic.

CONCLUSIONS

Our conclusions are as follows:

1. Dyslipidaemic patients are more likely to develop cortical opacification than the normal population.

2. Cortical lens opacification manifests at a younger age than does nuclear opacification.

3. It is essential that an abnormal lipid profile be diagnosed or detected as early as possible in order to achieve the maximum possible benefit from therapeutic intervention.

4. Cortical lens opacification in the patient younger than 50 years of age should alert the ophthalmologist to arrange for diagnostic serum lipid assessment.

5. The young patient with dyslipidaemia should undergo regular slit-lamp examination of the lens after full dilatation of the pupil in order to detect early signs of lens opacification.

6. Cortical lenticular opacification should be regarded as one of the most common, and hence reliable, clinical signs of dyslipidaemia.

References


